PredictCan Biotechnologies has published a new study in Translational Oncology demonstrating the application of its proprietary Cell Educating Technology™ to pancreatic ductal adenocarcinoma (PDAC). Conducted in close collaboration with clinicians from Montpellier University Hospital (CHU de Montpellier), the study represents an important step in extending PredictCan’s individual-centric technology to new cancer indications.
Using blood serum from patients with PDAC, the team generated patient serum-educated tumor spheroids and investigated whether their in vitro responses to anticancer treatments aligned with the clinical responses observed in the corresponding patients.
Connecting Individual In Vitro Response to Clinical Outcome
The retrospective, blinded case series used prospectively collected blood samples obtained before, during, and after treatment, enabling the researchers to investigate treatment response longitudinally.
The patient-educated models showed good concordance with individual clinical outcomes, providing proof-of-concept evidence that biological information carried by patient serum can be leveraged to generate individualized in vitro models reflecting clinically relevant treatment responses.
Importantly, longitudinal serum sampling also enabled changes in response to be investigated throughout treatment, illustrating the potential of the approach to capture the dynamic evolution of individual therapeutic response over time.
Toward More Predictive Preclinical Oncology
Interpatient heterogeneity remains one of the major challenges in anticancer drug development. Patients with the same cancer diagnosis may respond very differently to the same therapy, while conventional preclinical models often capture only a fraction of this biological diversity.
By generating individualized models from different patients, PredictCan aims to bring this diversity into drug development and enable anticancer compounds to be evaluated across multiple patient-specific biological backgrounds before clinical trials.
The PDAC study provides a proof of concept for this approach and establishes a foundation for further validation toward individualized treatment-response prediction in pancreatic cancer.
Expanding the Cell Educating Technology™ Beyond the Liver
The publication also represents an important milestone in the development of PredictCan’s technology.
Previous applications of the Cell Educating Technology™ have focused primarily on the liver, including drug-induced liver injury (DILI) and hepatocellular carcinoma (HCC). This study provides the first demonstration that the patented blood serum-derived approach can be successfully extended to pancreatic cancer, a distinct disease and biological context.
This versatility supports a broader vision for the technology: using the biological information contained within an individual’s serum to educate different cellular systems and generate individual-specific phenotypic models across multiple diseases and organ contexts.
For PredictCan, this represents an important step toward building a scalable platform capable of introducing human biological diversity across multiple areas of preclinical drug development.
